StockNow
Log in
U.S. Markets

FDA approves Lilly's (LLY) Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

StockNow breaking-news AI analysis

Eli Lilly evaluated tirzepatide across cardiovascular and metabolic indications, expanding Medicare access and advancing pipeline candidates alongside Mounjaro and Zepbound revenue growth.

1 stocks
LLYEli Lilly & Co.$1,168.49Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Fed

Fed's Hammack (2026 voter, hawkish dissenter) says inflation will end the year around 3% and that it is currently not meeting target

Politics

US Trump Administration is reportedly working on AI rules to reduce China's remote access to chips, The Information reports citing sources

Commodities

[MARKET UPDATE] Dutch TTF rises above EUR 70/MWh for the first time since March